Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
Kuros Biosurgery AG · with Simplified Clinical Data Systems, LLC, Kuros BioSciences B.V. · NCT04679844
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 60
- US sites recruiting
- 6
- Study start
- December 6, 2024
- Record last updated
- March 20, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
Being studied: MagnetOs Easypack Putty; Demineralized Bone Matrix or Fibers mixed with local autograft bone
Conditions: Degenerative Disc Disease; Spine Fusion; Back Pain
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
- Male or female patient ≥ 18 years old.
- Patients with segmental mechanical spinal instability requiring arthrodesis surgery.
Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:
- instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
- decreased disc height by > 2 mm, but dependent upon the spinal level
- Grade II or more listhesis
- TLICS equal or greater than 5
- Unstable burst fracture
- Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.
Exclusion Criteria
- Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
- Had prior PLF fusion or attempted PLF fusion at the involved levels.
- Had previous decompression at the involved levels.
- Women who are or intend to become pregnant within the next 12 months.
- To treat conditions in which general bone grafting is not advisable.
- In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
- In case of significant vascular impairment proximal to the graft site.
- In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
- In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
- When intraoperative soft tissue coverage is not planned or possible.
- Receiving treatment with medication interfering with calcium metabolism.
- Has degenerative disc disease (DDD) related to a benign or malignant tumor.
- Has history or presence of active malignancy.
- Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
- Is involved in active litigation relating to his/her spinal condition.
- Has participated in an investigational study within 30 days prior to surgery for study devices.
Recruiting US locations
The Regents of the University of California- Irvine Campus
Irvine, CA 92697
Site contact: Michael Oh, MD · ohm2@hs.uci.edu
Corewell Health
Grand Rapids, MI 49503
Site contact: Jason Squires, M · Jason.Squires@corewellhealth.org
The Washington University
St Louis, MO 63130
Site contact: Principal Investigator, Mark Lambrechts, MD
Rothman Orthopaedic Institute
Philadelphia, PA 19107
Site contact: Principal Investigator, Jose Canseco, MD
Tennessee Orthopaedic Alliance
Nashville, TN 37209
Site contact: Ryan Snowden, MD
University of Washington
Seattle, WA 98104
Site contact: Christoph Hofstetter, MD
Study contacts (from the official record)
- Cesar Silva, MD · 9702156793 · cesar.silva@kurosbio.com
Similar studies in California
All pain studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersEarly Phase 1
Brain Mechanisms Supporting Cannabis-induced Pain Relief
University of California, San Diego
- Location
- La Jolla, CA
- Eligibility basics
- Ages 21–65
- RecruitingPhase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Adneuris Therapeutics, Inc.
- Location
- Riverside, CA + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
Vertanical GmbH
- Location
- Long Beach, CA + 22 other US sites
- Eligibility basics
- Ages 18+